MDA-TIL

MDA-TIL is an autologous tumor-infiltrating lymphocyte (TIL) therapy developed by the M.D. Anderson Cancer Center. The therapeutic process involves the surgical resection of a patient's tumor tissue, from which naturally occurring T cells (TILs) are harvested. These cells are then expanded to large numbers ex vivo using high-dose interleukin-2 (IL-2). Once expanded, the MDA-TIL product is re-infused into the patient, typically following a lymphodepleting chemotherapy regimen consisting of cyclophosphamide and fludarabine. This approach leverages the ability of TILs to recognize a diverse, polyclonal array of tumor-specific neoantigens. Following infusion, patients usually receive IL-2 to support the survival and proliferation of the transferred T cells. MDA-TIL is currently being evaluated in Phase II clinical trials for the treatment of recurrent or refractory solid tumors, specifically ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.

Brand names

Amtagvi

Other names

Autologous Expanded Tumor Infiltrating LymphocytesAutologous Tumor Infiltrating Lymphocytes MDA-TILTumor Infiltrating Lymphocytes MDA-TIL